Clinical Trials | January 14, 2026
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
The state-of-the-art laboratory opens at the Corewell Health Southfield Center in early 2027
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Subscribe To Our Newsletter & Stay Updated
